Resistant Hypertension in Chronic Kidney Disease

(Brent) #1

320


References


  1. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor
    RG.  Sympathetic overactivity in patients with chronic renal failure. N Engl J  Med.
    1992;327:1912–8.

  2. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn
    KH. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106:1974–9.

  3. Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, Dell'Oro R,
    Mancia G. Early sympathetic activation in the initial clinical stages of chronic renal failure.
    Hypertension. 2011;57:846–51.

  4. Ye S, Zhong H, Yanamadala V, Campese VM.  Renal injury caused by intrarenal injection
    of phenol increases afferent and efferent renal sympathetic nerve activity. Am J  Hypertens.
    2002;15:717–24.

  5. Johns EJ, Abdulla MH.  Renal nerves in blood pressure regulation. Curr Opin Nephrol
    Hypertens. 2013;22:504–10.

  6. Penne EL, Neumann J, Klein IH, Oey PL, Bots ML, Blankestijn PJ. Sympathetic hyperactivity
    and clinical outcome in chronic kidney disease patients during standard treatment. J Nephrol.
    2009;22:208–15.

  7. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G,
    Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS. Plasma norepi-
    nephrine predicts survival and incident cardiovascular events in patients with end-stage renal
    disease. Circulation. 2002;105:1354–9.

  8. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266
    cases. J Am Med Assoc. 1953;152:1501–4.

  9. Sakakura K, Ladich E, Cheng Q, Otsuka F, Yahagi K, Fowler DR, Kolodgie FD, Virmani R,
    Joner M.  Anatomic assessment of sympathetic peri-arterial renal nerves in man. J  Am Coll
    Cardiol. 2014;640:635–43.

  10. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A,
    Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation
    for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet.
    2009;373:1275–81.

  11. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic
    denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a
    randomised controlled trial. Symplicity HTN-2 investigators. Lancet. 2010;376:1903–9.

  12. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu
    M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR.  Bakris GL;
    SYMPLICITY HTN-3 investigators. A controlled trial of renal denervation for resistant hyper-
    tension. N Engl J Med. 2014;370:1393–401.

  13. Rosa J, Widimsky P, Touek P, Petrak O, Curila K, Waldauf P, Bedna F, Zelinka T, Holaj R,
    Strauch B, Somloova Z, Taborsky M, Vaclavik J, Kocianova E, Branny M, Nykl I, Jiravsky
    O, Widimsky J. Randomized comparison of renal denervation versus intensified pharmaco-
    therapy including spironolactone in true-resistant hypertension: six-month results from the
    Prague-15 study. Hypertension. 2015;65(2):407–13.

  14. Desch S, Okon T, Heinemann D, Kulle K, Röhnert K, Sonnabend M, Petzold M, Müller U,
    Schuler G, Eitel I, Thiele H, Lurz P. Randomized sham-controlled trial of renal sympathetic
    denervation in mild resistant hypertension. Hypertension. 2015;65:1202–8.

  15. Bunte MC, Infante de Oliveira E, Shishehbor MH.  Endovascular treatment of resistant and
    uncontrolled hypertension: therapies on the horizon. JACC Cardiovasc Interv. 2013;6:1–9.

  16. Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, Sobotka PA, Böhm M,
    Cremers B, Esler MD, Schlaich MP. Renal denervation in moderate to severe CKD. J Am Soc
    Nephrol. 2012;23:1250–7.


M. Adamczak et al.
Free download pdf